2023 in review: FDA approvals of new medicines
Drug Discov Today. 2024 Mar 27:103966. doi: 10.1016/j.drudis.2024.103966. Online ahead of print.ABSTRACTAn analysis of all new entities approved by both the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) identified the approval of 68 {AuQ: Should this be 69 as shown in Figure 1A&B?} new entities in the year 2023, 50 % more than in the previous year. Oncology drugs tied with congenital and infectious diseases drugs for the most approvals. Although orphan and priority approvals continued at a high pace, the rate of fast-track approvals continued to decline. The ...
Source: Drug Discovery Today - March 29, 2024 Category: Drugs & Pharmacology Authors: Michael S Kinch Zachary Kraft Tyler Schwartz Source Type: research
Enzyme-responsive design combined with photodynamic therapy for cancer treatment
Drug Discov Today. 2024 Mar 27:103965. doi: 10.1016/j.drudis.2024.103965. Online ahead of print.ABSTRACTPhotodynamic therapy (PDT) is a noninvasive cancer treatment that has garnered significant attention in recent years. However, its application is still hampered by certain limitations, such as the hydrophobicity and low targeting of photosensitizers (PSs) and the hypoxia of the tumor microenvironment. Nevertheless, the fusion of enzyme-responsive drugs with PDT offers novel solutions to overcome these challenges. Utilizing the attributes of enzyme-responsive drugs, PDT can deliver PSs to the target site and selectively r...
Source: Drug Discovery Today - March 29, 2024 Category: Drugs & Pharmacology Authors: Siying Zhi Meixin Huang Kui Cheng Source Type: research
Physical and mechanical properties of ocular thin films: a systematic review and meta-analysis
Drug Discov Today. 2024 Mar 27:103964. doi: 10.1016/j.drudis.2024.103964. Online ahead of print.ABSTRACTThe ocular thin film presents a potential solution for addressing challenges to ocular drug delivery. In this review, we summarise the findings of a comprehensive review analysing 336 formulations from 68 studies. We investigated the physical and mechanical properties of ocular thin films, categorised into natural polymer-based, synthetic polymer-based, and combined polymer films. The results showed that the type of polymers used impacted mucoadhesion force, moisture absorption:moisture loss ratio, pH, swelling index, an...
Source: Drug Discovery Today - March 29, 2024 Category: Drugs & Pharmacology Authors: Mitra Farahmandnejad Shohre Alipour Ali Nokhodchi Source Type: research
Tuberculosis treatment-shortening
Drug Discov Today. 2024 Mar 26:103955. doi: 10.1016/j.drudis.2024.103955. Online ahead of print.ABSTRACTTuberculosis (TB) presents a significant global health concern, with ∼10 million people developing TB and 1.3 million people dying from the disease each year. The standard treatment regimen for drug-susceptible TB was between 6 and 9 months until recently, presenting a prolonged therapeutic duration compared with other infectious diseases. This is a long time for patients to adhere to the medication, consequently increasing the risk of developing drug-resistant Mycobacterium tuberculosis - a significant challenge in TB...
Source: Drug Discovery Today - March 28, 2024 Category: Drugs & Pharmacology Authors: Vinayak Singh Source Type: research
Tuberculosis treatment-shortening
Drug Discov Today. 2024 Mar 26:103955. doi: 10.1016/j.drudis.2024.103955. Online ahead of print.ABSTRACTTuberculosis (TB) presents a significant global health concern, with ∼10 million people developing TB and 1.3 million people dying from the disease each year. The standard treatment regimen for drug-susceptible TB was between 6 and 9 months until recently, presenting a prolonged therapeutic duration compared with other infectious diseases. This is a long time for patients to adhere to the medication, consequently increasing the risk of developing drug-resistant Mycobacterium tuberculosis - a significant challenge in TB...
Source: Drug Discovery Today - March 28, 2024 Category: Drugs & Pharmacology Authors: Vinayak Singh Source Type: research
Design, development, and technical considerations for dry powder inhaler devices
Drug Discov Today. 2024 Mar 24:103954. doi: 10.1016/j.drudis.2024.103954. Online ahead of print.ABSTRACTThe dry powder inhaler (DPI) stands out as a highly patient-friendly and effective pulmonary formulation, surpassing traditional and other pulmonary dosage forms in certain disease conditions. The development of DPI products, however, presents more complexities than that of other dosage forms, particularly in device design and the integration of the drug formulation. This review focuses on the capabilities of DPI devices in pulmonary drug delivery, with a special emphasis on device design and formulation development. It ...
Source: Drug Discovery Today - March 26, 2024 Category: Drugs & Pharmacology Authors: Sagar Dhoble Archana Kapse Vaibhav Ghegade Manasi Chogale Vinod Ghodake Vandana Patravale Lalitkumar Vora Source Type: research
Design, development, and technical considerations for dry powder inhaler devices
Drug Discov Today. 2024 Mar 24:103954. doi: 10.1016/j.drudis.2024.103954. Online ahead of print.ABSTRACTThe dry powder inhaler (DPI) stands out as a highly patient-friendly and effective pulmonary formulation, surpassing traditional and other pulmonary dosage forms in certain disease conditions. The development of DPI products, however, presents more complexities than that of other dosage forms, particularly in device design and the integration of the drug formulation. This review focuses on the capabilities of DPI devices in pulmonary drug delivery, with a special emphasis on device design and formulation development. It ...
Source: Drug Discovery Today - March 26, 2024 Category: Drugs & Pharmacology Authors: Sagar Dhoble Archana Kapse Vaibhav Ghegade Manasi Chogale Vinod Ghodake Vandana Patravale Lalitkumar Vora Source Type: research
Peptide-derived ligands for the discovery of safer opioid analgesics
Drug Discov Today. 2024 Mar 19:103950. doi: 10.1016/j.drudis.2024.103950. Online ahead of print.ABSTRACTDrugs targeting the μ-opioid receptor (MOR) remain the most efficacious analgesics for the treatment of pain, but activation of MOR with current opioid analgesics also produces harmful side effects, notably physical dependence, addiction, and respiratory depression. Opioid peptides have been accepted as promising candidates for the development of safer and more efficacious analgesics. To develop peptide-based opioid analgesics, strategies such as modification of endogenous opioid peptides, development of multifunctional...
Source: Drug Discovery Today - March 21, 2024 Category: Drugs & Pharmacology Authors: Abbe Eliasof Lee-Yuan Liu-Chen Yangmei Li Source Type: research
Small molecules targeting canonical transient receptor potential channels: an update
Drug Discov Today. 2024 Mar 20:103951. doi: 10.1016/j.drudis.2024.103951. Online ahead of print.ABSTRACTTransient receptor potential canonical (TRPC) channels belong to an important class of non-selective cation channels. This channel family consists of multiple members that widely participate in various physiological and pathological processes. Previous studies have uncovered the intricate regulation of these channels, as well as the spatial arrangement of TRPCs and the binding sites for various small molecule compounds. Multiple small molecules have been identified as selective agonists or inhibitors targeting different ...
Source: Drug Discovery Today - March 21, 2024 Category: Drugs & Pharmacology Authors: Hua Liu Min Fu Yifan Zhang Qidong You Lei Wang Source Type: research
Peptide-derived ligands for the discovery of safer opioid analgesics
Drug Discov Today. 2024 Mar 19:103950. doi: 10.1016/j.drudis.2024.103950. Online ahead of print.ABSTRACTDrugs targeting the μ-opioid receptor (MOR) remain the most efficacious analgesics for the treatment of pain, but activation of MOR with current opioid analgesics also produces harmful side effects, notably physical dependence, addiction, and respiratory depression. Opioid peptides have been accepted as promising candidates for the development of safer and more efficacious analgesics. To develop peptide-based opioid analgesics, strategies such as modification of endogenous opioid peptides, development of multifunctional...
Source: Drug Discovery Today - March 21, 2024 Category: Drugs & Pharmacology Authors: Abbe Eliasof Lee-Yuan Liu-Chen Yangmei Li Source Type: research
Small molecules targeting canonical transient receptor potential channels: an update
Drug Discov Today. 2024 Mar 20:103951. doi: 10.1016/j.drudis.2024.103951. Online ahead of print.ABSTRACTTransient receptor potential canonical (TRPC) channels belong to an important class of non-selective cation channels. This channel family consists of multiple members that widely participate in various physiological and pathological processes. Previous studies have uncovered the intricate regulation of these channels, as well as the spatial arrangement of TRPCs and the binding sites for various small molecule compounds. Multiple small molecules have been identified as selective agonists or inhibitors targeting different ...
Source: Drug Discovery Today - March 21, 2024 Category: Drugs & Pharmacology Authors: Hua Liu Min Fu Yifan Zhang Qidong You Lei Wang Source Type: research
Peptide-derived ligands for the discovery of safer opioid analgesics
Drug Discov Today. 2024 Mar 19:103950. doi: 10.1016/j.drudis.2024.103950. Online ahead of print.ABSTRACTDrugs targeting the μ-opioid receptor (MOR) remain the most efficacious analgesics for the treatment of pain, but activation of MOR with current opioid analgesics also produces harmful side effects, notably physical dependence, addiction, and respiratory depression. Opioid peptides have been accepted as promising candidates for the development of safer and more efficacious analgesics. To develop peptide-based opioid analgesics, strategies such as modification of endogenous opioid peptides, development of multifunctional...
Source: Drug Discovery Today - March 21, 2024 Category: Drugs & Pharmacology Authors: Abbe Eliasof Lee-Yuan Liu-Chen Yangmei Li Source Type: research
Small molecules targeting canonical transient receptor potential channels: an update
Drug Discov Today. 2024 Mar 19:103951. doi: 10.1016/j.drudis.2024.103951. Online ahead of print.ABSTRACTTransient receptor potential canonical (TRPC) channels belong to an important class of non-selective cation channels. This channel family consists of multiple members that widely participate in various physiological and pathological processes. Previous studies have uncovered the intricate regulation of these channels, as well as the spatial arrangement of TRPCs and the binding sites for various small molecule compounds. Multiple small molecules have been identified as selective agonists or inhibitors targeting different ...
Source: Drug Discovery Today - March 21, 2024 Category: Drugs & Pharmacology Authors: Hua Liu Min Fu Yifan Zhang Qidong You Lei Wang Source Type: research
Peptide-derived ligands for the discovery of safer opioid analgesics
Drug Discov Today. 2024 Mar 19:103950. doi: 10.1016/j.drudis.2024.103950. Online ahead of print.ABSTRACTDrugs targeting the μ-opioid receptor (MOR) remain the most efficacious analgesics for the treatment of pain, but activation of MOR with current opioid analgesics also produces harmful side effects, notably physical dependence, addiction, and respiratory depression. Opioid peptides have been accepted as promising candidates for the development of safer and more efficacious analgesics. To develop peptide-based opioid analgesics, strategies such as modification of endogenous opioid peptides, development of multifunctional...
Source: Drug Discovery Today - March 21, 2024 Category: Drugs & Pharmacology Authors: Abbe Eliasof Lee-Yuan Liu-Chen Yangmei Li Source Type: research
Small molecules targeting canonical transient receptor potential channels: an update
Drug Discov Today. 2024 Mar 19:103951. doi: 10.1016/j.drudis.2024.103951. Online ahead of print.ABSTRACTTransient receptor potential canonical (TRPC) channels belong to an important class of non-selective cation channels. This channel family consists of multiple members that widely participate in various physiological and pathological processes. Previous studies have uncovered the intricate regulation of these channels, as well as the spatial arrangement of TRPCs and the binding sites for various small molecule compounds. Multiple small molecules have been identified as selective agonists or inhibitors targeting different ...
Source: Drug Discovery Today - March 21, 2024 Category: Drugs & Pharmacology Authors: Hua Liu Min Fu Yifan Zhang Qidong You Lei Wang Source Type: research
